Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Inventory (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Inventory data on record, last reported at $21.3 million in Q3 2025.

  • For Q3 2025, Inventory rose 23.58% year-over-year to $21.3 million; the TTM value through Sep 2025 reached $21.3 million, up 23.58%, while the annual FY2024 figure was $21.2 million, 11.54% up from the prior year.
  • Inventory reached $21.3 million in Q3 2025 per PLX's latest filing, up from $21.1 million in the prior quarter.
  • Across five years, Inventory topped out at $22.3 million in Q1 2024 and bottomed at $13.6 million in Q2 2021.
  • Average Inventory over 5 years is $18.4 million, with a median of $19.0 million recorded in 2023.
  • Peak YoY movement for Inventory: skyrocketed 48.21% in 2023, then dropped 20.31% in 2024.
  • A 5-year view of Inventory shows it stood at $18.0 million in 2021, then dropped by 6.41% to $16.8 million in 2022, then rose by 13.34% to $19.0 million in 2023, then rose by 11.54% to $21.2 million in 2024, then grew by 0.06% to $21.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $21.3 million in Q3 2025, $21.1 million in Q2 2025, and $19.5 million in Q1 2025.